Language
English
Publication Date
11-7-2022
Journal
International Journal of Environmental Research and Public Health
DOI
10.3390/ijerph192114607
PMID
36361485
PMCID
PMC9654308
PubMedCentral® Posted Date
11-7-2022
PubMedCentral® Full Text Version
Post-print
Abstract
Cystatin C is a specific biomarker of kidney function. We perform this meta-analysis to determine the association of Cystatin C with the COVID-19 severity. In this systematic review and meta-analysis, we searched PubMed, EMBASE, Cochrane library, and Web of Science for studies published until 2nd September 2022 that reported associations between Cystatin C levels and COVID-19 severity. The analysis was performed using a random-effects model to calculate pooled standard mean difference (SMD). Twenty-five studies were included in the meta-analysis. Pooled analysis showed statistically significant differences of Cystatin C levels among survive vs. decreased patients (0.998 ± 0.225 vs. 1.328 ± 0.475 mg/dL, respectively; SMD = -2.14; 95%CI: -3.28 to -1.01;
Keywords
Humans, Acute Kidney Injury, Biomarkers, COVID-19, Cystatin C, Prognosis, Cystatin C, cystatin 3, SARS-CoV-2, novel coronavirus, COVID-19, severity
Published Open-Access
yes
Recommended Citation
Matuszewski, Michal; Reznikov, Yurii; Pruc, Michal; et al., "Prognostic Performance of Cystatin C in COVID-19: A Systematic Review and Meta-Analysis" (2022). Faculty and Staff Publications. 3918.
https://digitalcommons.library.tmc.edu/baylor_docs/3918
Included in
Clinical Epidemiology Commons, COVID-19 Commons, Medical Sciences Commons, Medical Specialties Commons